Pub Date : 2025-09-26DOI: 10.1016/j.clml.2025.09.016
Natalie Tuckey , Matthew Iasiello , Kathina Ali , Angelina Yong , Sophie Wilson , Mark Ryan , Dominic Scoleri , Melissa Cantley , Hannah R Wardill
Multiple myeloma is the second most common blood cancer caused by the uncontrolled growth of abnormal plasma cells in the bone marrow. It is currently incurable, requiring multiple lines of therapy that can control, but do not cure, the disease. People with myeloma often report high levels of anxiety and depression and are reported to have the lowest quality of life of any cancer type likely due to the incurable nature of the disease. Despite the significant mental health burden, interventions to address the psychological impact of myeloma and its precursor conditions, smoldering myeloma and monoclonal gammopathy of undetermined significance, are limited. This review found that existing psychosocial interventions are limited in scope and quality, often involving small samples, inconsistent methods, and short-term outcomes. Most lack consumer co-design and implementation frameworks, reducing their sustainability and real-world impact. Interventions rarely address the complex and overlapping physical and psychological needs of patients, such as pain, fatigue, body image, and uncertainty, and few integrate mental health support into exercise programs. Caregivers, despite their significant emotional strain, are also frequently excluded from support strategies. There is a clear need for comprehensive, co-designed interventions that reflect the diverse experiences of those affected and address both physical and psychological challenges. Prioritizing implementation and sustainability can enhance mental health outcomes, reduce healthcare burden, and improve the quality of supportive cancer care.
{"title":"The Unmet Psychological Needs of People Living With Multiple Myeloma and Smouldering Myeloma: A Review of Current Approaches and Future Directions","authors":"Natalie Tuckey , Matthew Iasiello , Kathina Ali , Angelina Yong , Sophie Wilson , Mark Ryan , Dominic Scoleri , Melissa Cantley , Hannah R Wardill","doi":"10.1016/j.clml.2025.09.016","DOIUrl":"10.1016/j.clml.2025.09.016","url":null,"abstract":"<div><div>Multiple myeloma is the second most common blood cancer caused by the uncontrolled growth of abnormal plasma cells in the bone marrow. It is currently incurable, requiring multiple lines of therapy that can control, but do not cure, the disease. People with myeloma often report high levels of anxiety and depression and are reported to have the lowest quality of life of any cancer type likely due to the incurable nature of the disease. Despite the significant mental health burden, interventions to address the psychological impact of myeloma and its precursor conditions, smoldering myeloma and monoclonal gammopathy of undetermined significance, are limited. This review found that existing psychosocial interventions are limited in scope and quality, often involving small samples, inconsistent methods, and short-term outcomes. Most lack consumer co-design and implementation frameworks, reducing their sustainability and real-world impact. Interventions rarely address the complex and overlapping physical and psychological needs of patients, such as pain, fatigue, body image, and uncertainty, and few integrate mental health support into exercise programs. Caregivers, despite their significant emotional strain, are also frequently excluded from support strategies. There is a clear need for comprehensive, co-designed interventions that reflect the diverse experiences of those affected and address both physical and psychological challenges. Prioritizing implementation and sustainability can enhance mental health outcomes, reduce healthcare burden, and improve the quality of supportive cancer care.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 12","pages":"Pages e1145-e1159"},"PeriodicalIF":2.7,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-10DOI: 10.1016/j.clml.2025.09.005
Dan Li, Jiongping Han, Jing Jin, Li Hong, Pan Hong, Weiying Feng
Background: Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, and death from non-WM causes has become increasingly important in treatment decisions. This study explored the causes of death in WM patients.
Methods: The data from 8894 patients diagnosed with WM in the Surveillance, Epidemiology, and End Results (SEER) database from 1980 to 2016 were included. Standardized mortality ratios (SMRs) were used to assess the relative risk of death compared with that of the general US population.
Results: Considering other competing events, the 5-year cumulative incidences of death from the index cancer, SMNs and noncancer causes were 8.6% (SD: 1.00e-05), 10.02% (SD: 1.17e-05) and 16.14% (SD: 1.79e-05), respectively, among WM patients. WM patients had the highest SMR for index cancer-related death, at 121.84 (95% CI, 103.8-142.11) in the first year after diagnosis, which declined thereafter. Among nonindex cancer-related deaths, hematological malignancy-related deaths were notably increased, whereas solid neoplasm deaths were elevated only 10 years after diagnosis (SMR, 1.43; 95% CI, 1.06-1.9). Among noncancer causes of death, infection, particularly among patients <50 years old, had the highest SMR (SMR, 19.01; 95% CI, 10.12-32.5). There were decreasing trends in the SMRs of index cancer-related deaths, all nonindex cancer-related deaths and many noncancer disease-related deaths from 1980 to 2001 and 2002 to 2016.
Conclusions: Currently, the risk of noncancer-related deaths (mainly cardiovascular disease-related deaths) exceeds that of cancer-related deaths among WM patients. These findings may provide improved guidance regarding future health risks for WM patients.
{"title":"Causes of Death Among Waldenström Macroglobulinemia Patients: A Population-Based Study.","authors":"Dan Li, Jiongping Han, Jing Jin, Li Hong, Pan Hong, Weiying Feng","doi":"10.1016/j.clml.2025.09.005","DOIUrl":"https://doi.org/10.1016/j.clml.2025.09.005","url":null,"abstract":"<p><strong>Background: </strong>Waldenström macroglobulinemia (WM) is a rare, indolent lymphoma, and death from non-WM causes has become increasingly important in treatment decisions. This study explored the causes of death in WM patients.</p><p><strong>Methods: </strong>The data from 8894 patients diagnosed with WM in the Surveillance, Epidemiology, and End Results (SEER) database from 1980 to 2016 were included. Standardized mortality ratios (SMRs) were used to assess the relative risk of death compared with that of the general US population.</p><p><strong>Results: </strong>Considering other competing events, the 5-year cumulative incidences of death from the index cancer, SMNs and noncancer causes were 8.6% (SD: 1.00e-05), 10.02% (SD: 1.17e-05) and 16.14% (SD: 1.79e-05), respectively, among WM patients. WM patients had the highest SMR for index cancer-related death, at 121.84 (95% CI, 103.8-142.11) in the first year after diagnosis, which declined thereafter. Among nonindex cancer-related deaths, hematological malignancy-related deaths were notably increased, whereas solid neoplasm deaths were elevated only 10 years after diagnosis (SMR, 1.43; 95% CI, 1.06-1.9). Among noncancer causes of death, infection, particularly among patients <50 years old, had the highest SMR (SMR, 19.01; 95% CI, 10.12-32.5). There were decreasing trends in the SMRs of index cancer-related deaths, all nonindex cancer-related deaths and many noncancer disease-related deaths from 1980 to 2001 and 2002 to 2016.</p><p><strong>Conclusions: </strong>Currently, the risk of noncancer-related deaths (mainly cardiovascular disease-related deaths) exceeds that of cancer-related deaths among WM patients. These findings may provide improved guidance regarding future health risks for WM patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-10DOI: 10.1016/j.clml.2025.09.006
Colin J Thomas, Stefan K Barta
T-cell non-Hodgkin lymphomas (NHL) are a heterogenous group of malignancies that represent a minority of all NHL cases world-wide. Outcomes with traditional chemotherapy-based regimens remain poor with notably dismal outcomes in the relapsed/refractory setting. The power of immunotherapy has revolutionized treatments and outcomes for hematologic malignancies and has already made significant strides in addressing the treatment needs in T-cell NHLs. Given the heterogeneity of T-cell lymphoma subtypes and biology, a wide variety of innovative immunotherapies have been evolving to treat these various malignancies. Here, we review the promising advancement of various immunotherapies in T-cell NHLs including antibody-based therapies targeting T-cell surface antigens and checkpoint signaling, as well as the expanding strategies for chimeric antigen receptor T-cell (CAR-T) therapy in this difficult to treat disease space.
{"title":"The Promise of Immunotherapies in T-Cell Lymphoma.","authors":"Colin J Thomas, Stefan K Barta","doi":"10.1016/j.clml.2025.09.006","DOIUrl":"https://doi.org/10.1016/j.clml.2025.09.006","url":null,"abstract":"<p><p>T-cell non-Hodgkin lymphomas (NHL) are a heterogenous group of malignancies that represent a minority of all NHL cases world-wide. Outcomes with traditional chemotherapy-based regimens remain poor with notably dismal outcomes in the relapsed/refractory setting. The power of immunotherapy has revolutionized treatments and outcomes for hematologic malignancies and has already made significant strides in addressing the treatment needs in T-cell NHLs. Given the heterogeneity of T-cell lymphoma subtypes and biology, a wide variety of innovative immunotherapies have been evolving to treat these various malignancies. Here, we review the promising advancement of various immunotherapies in T-cell NHLs including antibody-based therapies targeting T-cell surface antigens and checkpoint signaling, as well as the expanding strategies for chimeric antigen receptor T-cell (CAR-T) therapy in this difficult to treat disease space.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-09DOI: 10.1016/j.clml.2025.09.004
Dong Won Baek , Sang Kyun Sohn , Sung-Hoon Jung , Ga-Young Song , Ik-Chan Song , Jeong Suk Koh , Ho-Jin Shin , Do Young Kim , Sung-Hyun Kim , Ji Hyun Lee , Sung-Nam Lim , Won Sik Lee , Young Rok Do , Min Kyoung Kim , Young Hoon Park , Hyeon-Seok Eom , Ki Sun Jung , Jee Hyun Kong , Joon Ho Moon , Adult Acute Lymphoblastic Leukemia Working Party, the Korean Society of Hematology
Background
This study analyzed the long-term survival of blinatumomab-treated patients in the salvage setting and factors affecting treatment outcomes.
Methods
Clinical data were collected from adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) who were administered blinatumomab as a salvage therapy.
Results
A total of 138 patients with R/R B-cell ALL were analyzed, of which 99 patients were diagnosed with Philadelphia chromosome-negative (Ph-negative) ALL, and 39 patients were treated for Ph-positive ALL. After 2 cycles of blinatumomab therapy, 45 patients (45.5%) achieved complete remission (CR), and 10 (10.1%) showed complete remission with partial hematological response (CRh), while 32 (32.3%) showed no response in the Ph-negative ALL subgroup. In the Ph-positive ALL subgroup, 18 patients (46.2%) achieved CR, and 4 (10.3%) achieved CRh, while 13 (33.3%) were refractory. In the Ph-negative ALL subgroup, for both relapse-free survival (RFS) and overall survival (OS), PLT < 100.0 (× 103/µL) and number of prior treatment lines ≥ 2 were adverse prognostic factors, while proceeding to allo-SCT was a favorable factor. In the Ph-positive ALL subgroup, number of prior treatment lines ≥ 3 and refractory status at blinatumomab initiation were adverse factors for RFS. PLT < 100.0 (× 103/µL) and refractory status were adverse factors, while proceeding to allo-SCT was a favorable factor for OS.
Conclusion
Early use of blinatumomab showed survival benefits in both Ph-negative and Ph-positive ALL subgroups in the salvage setting. Proceeding to allo-SCT after blinatumomab could improve long-term outcomes in patients with Ph-negative ALL.
{"title":"Survival Benefits of Early Treatment With Blinatumomab in Adult Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia","authors":"Dong Won Baek , Sang Kyun Sohn , Sung-Hoon Jung , Ga-Young Song , Ik-Chan Song , Jeong Suk Koh , Ho-Jin Shin , Do Young Kim , Sung-Hyun Kim , Ji Hyun Lee , Sung-Nam Lim , Won Sik Lee , Young Rok Do , Min Kyoung Kim , Young Hoon Park , Hyeon-Seok Eom , Ki Sun Jung , Jee Hyun Kong , Joon Ho Moon , Adult Acute Lymphoblastic Leukemia Working Party, the Korean Society of Hematology","doi":"10.1016/j.clml.2025.09.004","DOIUrl":"10.1016/j.clml.2025.09.004","url":null,"abstract":"<div><h3>Background</h3><div>This study analyzed the long-term survival of blinatumomab-treated patients in the salvage setting and factors affecting treatment outcomes.</div></div><div><h3>Methods</h3><div>Clinical data were collected from adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) who were administered blinatumomab as a salvage therapy.</div></div><div><h3>Results</h3><div>A total of 138 patients with R/R B-cell ALL were analyzed, of which 99 patients were diagnosed with Philadelphia chromosome-negative (Ph-negative) ALL, and 39 patients were treated for Ph-positive ALL. After 2 cycles of blinatumomab therapy, 45 patients (45.5%) achieved complete remission (CR), and 10 (10.1%) showed complete remission with partial hematological response (CRh), while 32 (32.3%) showed no response in the Ph-negative ALL subgroup. In the Ph-positive ALL subgroup, 18 patients (46.2%) achieved CR, and 4 (10.3%) achieved CRh, while 13 (33.3%) were refractory. In the Ph-negative ALL subgroup, for both relapse-free survival (RFS) and overall survival (OS), PLT < 100.0 (× 10<sup>3</sup>/µL) and number of prior treatment lines ≥ 2 were adverse prognostic factors, while proceeding to allo-SCT was a favorable factor. In the Ph-positive ALL subgroup, number of prior treatment lines ≥ 3 and refractory status at blinatumomab initiation were adverse factors for RFS. PLT < 100.0 (× 10<sup>3</sup>/µL) and refractory status were adverse factors, while proceeding to allo-SCT was a favorable factor for OS.</div></div><div><h3>Conclusion</h3><div>Early use of blinatumomab showed survival benefits in both Ph-negative and Ph-positive ALL subgroups in the salvage setting. Proceeding to allo-SCT after blinatumomab could improve long-term outcomes in patients with Ph-negative ALL.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 12","pages":"Pages e1160-e1172.e8"},"PeriodicalIF":2.7,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-03DOI: 10.1016/j.clml.2025.09.002
Uday Yanamandra , Celine Raphael , Roopika Peela , Abu Jafar Mohammad Saleh , Thinley Dorji , Hassan Juneh , Aye Aye Gyi , Ajay Jha , Mohammad Ayaz Mir , Buddhika Somawardana , Amin Lutful Kabir , Bishesh Poudyal , Manu Wimalachandra , Zeba Aziz , Senani Williams , Saad Usmani , Shaji Kumar , Pankaj Malhotra
<div><h3>Background</h3><div>Multiple myeloma (MM) is a hematological malignancy with rising incidence globally, including in South Asia. Despite advances in treatment, access to essential drugs, diagnostic tools, and stem cell transplantation remains inconsistent across the region. This study assesses the availability, accessibility, and cost of MM treatments in South Asian countries to identify gaps in care and inform healthcare policy.</div></div><div><h3>Methods</h3><div>A cross-sectional, descriptive study was conducted through a web-based survey targeting physicians managing MM patients in Bangladesh, Bhutan, India, Maldives, Myanmar, Nepal, Pakistan, and Sri Lanka. The survey covered institutional healthcare structures, drug availability, treatment regimens, diagnostic access, and patient out-of-pocket expenditures (OOPE). Data were analyzed to evaluate disparities in MM care across public and private healthcare sectors.</div></div><div><h3>Results</h3><div>Public and private healthcare institutions coexist in all studied countries except Bhutan, where MM care is primarily public. Physicians reported a high OOPE for MM treatment, with patients covering an average of 70% of total medical costs. Key diagnostic investigations such as serum protein electrophoresis, immunofixation, and free light chain assays were unavailable in public hospitals in 62.5% of the countries, while minimal residual disease estimation via flow cytometry was available publicly only in India. PET scans were available in public hospitals in India, Bangladesh, Sri Lanka, and Pakistan, but remained cost-prohibitive. Lenalidomide and bortezomib were available in public institutions in 75% of the countries, while advanced therapies like daratumumab were largely restricted to private institutions in 62.5% of the countries. IV melphalan was unavailable in public institutions in 62.5% of the countries. Autologous stem cell transplant (ASCT) centers were reported in 75% of the studied countries; however, cryopreservation facilities were limited to 25% of the countries, and mobilization agents like plerixafor were accessible in 62.5%. The most commonly used first-line therapy for transplant-eligible patients in public institutions was VRd (bortezomib, lenalidomide, dexamethasone) in 50% of the countries, while private institutions more frequently incorporated daratumumab (VRd-D). Only India had a dedicated myeloma patient support group, whereas general oncology support groups were reported in 62.5% of the countries.</div></div><div><h3>Conclusions</h3><div>There are significant disparities in MM treatment accessibility across South Asia. Public sector institutions often lack essential diagnostic tools and advanced therapies, forcing patients to rely on private healthcare at high OOPE. Improved government policies, financial assistance programs, and public-private partnerships are needed to enhance drug accessibility, diagnostic infrastructure, and transplant availability.</div>
{"title":"Treatment Accessibility, Availability, and Healthcare Costs for Multiple Myeloma in South Asian Countries","authors":"Uday Yanamandra , Celine Raphael , Roopika Peela , Abu Jafar Mohammad Saleh , Thinley Dorji , Hassan Juneh , Aye Aye Gyi , Ajay Jha , Mohammad Ayaz Mir , Buddhika Somawardana , Amin Lutful Kabir , Bishesh Poudyal , Manu Wimalachandra , Zeba Aziz , Senani Williams , Saad Usmani , Shaji Kumar , Pankaj Malhotra","doi":"10.1016/j.clml.2025.09.002","DOIUrl":"10.1016/j.clml.2025.09.002","url":null,"abstract":"<div><h3>Background</h3><div>Multiple myeloma (MM) is a hematological malignancy with rising incidence globally, including in South Asia. Despite advances in treatment, access to essential drugs, diagnostic tools, and stem cell transplantation remains inconsistent across the region. This study assesses the availability, accessibility, and cost of MM treatments in South Asian countries to identify gaps in care and inform healthcare policy.</div></div><div><h3>Methods</h3><div>A cross-sectional, descriptive study was conducted through a web-based survey targeting physicians managing MM patients in Bangladesh, Bhutan, India, Maldives, Myanmar, Nepal, Pakistan, and Sri Lanka. The survey covered institutional healthcare structures, drug availability, treatment regimens, diagnostic access, and patient out-of-pocket expenditures (OOPE). Data were analyzed to evaluate disparities in MM care across public and private healthcare sectors.</div></div><div><h3>Results</h3><div>Public and private healthcare institutions coexist in all studied countries except Bhutan, where MM care is primarily public. Physicians reported a high OOPE for MM treatment, with patients covering an average of 70% of total medical costs. Key diagnostic investigations such as serum protein electrophoresis, immunofixation, and free light chain assays were unavailable in public hospitals in 62.5% of the countries, while minimal residual disease estimation via flow cytometry was available publicly only in India. PET scans were available in public hospitals in India, Bangladesh, Sri Lanka, and Pakistan, but remained cost-prohibitive. Lenalidomide and bortezomib were available in public institutions in 75% of the countries, while advanced therapies like daratumumab were largely restricted to private institutions in 62.5% of the countries. IV melphalan was unavailable in public institutions in 62.5% of the countries. Autologous stem cell transplant (ASCT) centers were reported in 75% of the studied countries; however, cryopreservation facilities were limited to 25% of the countries, and mobilization agents like plerixafor were accessible in 62.5%. The most commonly used first-line therapy for transplant-eligible patients in public institutions was VRd (bortezomib, lenalidomide, dexamethasone) in 50% of the countries, while private institutions more frequently incorporated daratumumab (VRd-D). Only India had a dedicated myeloma patient support group, whereas general oncology support groups were reported in 62.5% of the countries.</div></div><div><h3>Conclusions</h3><div>There are significant disparities in MM treatment accessibility across South Asia. Public sector institutions often lack essential diagnostic tools and advanced therapies, forcing patients to rely on private healthcare at high OOPE. Improved government policies, financial assistance programs, and public-private partnerships are needed to enhance drug accessibility, diagnostic infrastructure, and transplant availability.</div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 12","pages":"Pages e1134-e1144"},"PeriodicalIF":2.7,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/S2152-2650(25)03494-9
Christopher Ferreri, Mansi Shah, Rajshekhar Chakraborty, Don Stevens, Aurora Breazna, Oluwaseun Aina, Anita Boyapati, Colby Shemesh, Steven Quatela, Robert Orlowski
{"title":"Linvoseltamab (LINVO) Monotherapy in Patients (pts) with Newly Diagnosed (ND) Multiple Myeloma (MM): Initial Dose-Escalation Results from the Window of Opportunity LINKER-MM4 Trial","authors":"Christopher Ferreri, Mansi Shah, Rajshekhar Chakraborty, Don Stevens, Aurora Breazna, Oluwaseun Aina, Anita Boyapati, Colby Shemesh, Steven Quatela, Robert Orlowski","doi":"10.1016/S2152-2650(25)03494-9","DOIUrl":"10.1016/S2152-2650(25)03494-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 ","pages":"Page S60"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145095088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/S2152-2650(25)03429-9
Mattia D’Agostino, Mark van Duin, Wilfried Roeloffzen, Meletios Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez-Otero, Roman Hájek, Daniela Oddolo, Esther de Waal, Enrique Ocio, Mark-David Levin, María-Victoria Mateos, Paula Ypma, Fredrik Schjesvold, Joan Bladé, Francesca Gay
{"title":"High Accuracy of Next-Generation Flow (NGF) in Predicting Measurable Residual Disease by Next-Generation Sequencing (NGS) in the 10−6 Range: A Prospective Comparison Within the Phase III IsKia Trial","authors":"Mattia D’Agostino, Mark van Duin, Wilfried Roeloffzen, Meletios Dimopoulos, Laura Rosiñol, Marjolein van der Klift, Roberto Mina, Albert Oriol, Eirini Katodritou, Ka Lung Wu, Paula Rodríguez-Otero, Roman Hájek, Daniela Oddolo, Esther de Waal, Enrique Ocio, Mark-David Levin, María-Victoria Mateos, Paula Ypma, Fredrik Schjesvold, Joan Bladé, Francesca Gay","doi":"10.1016/S2152-2650(25)03429-9","DOIUrl":"10.1016/S2152-2650(25)03429-9","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 ","pages":"Pages S17-S18"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145098346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号